Bank Of New York Mellon Corp Affimed N.V. Transaction History

Bank Of New York Mellon Corp

$538 Trillion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.66 - $1.29 $235,519 - $460,332	356,847 New	356,847 $266 Million
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $396,825 - $883,837	360,750 New	360,750 $447,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $67,896 - $115,008	34,641 Added 10.57%	362,413 $746,000
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $56,829 - $121,670	25,035 Added 8.27%	327,772 $908,000
Q1 2022 May 11, 2022	BUY	$3.69 - $5.65 $20,342 - $31,148	5,513 Added 1.85%	302,737 $1.32 Million
Q4 2021 Feb 11, 2022	BUY	$5.37 - $7.07 $50,365 - $66,309	9,379 Added 3.26%	297,224 $1.64 Million
Q3 2021 Nov 12, 2021	SELL	$5.54 - $7.51 $476,445 - $645,867	-86,001 Reduced 23.0%	287,845 $1.78 Million
Q2 2021 Aug 11, 2021	SELL	$7.78 - $11.4 $18,197 - $26,664	-2,339 Reduced 0.62%	373,846 $3.18 Million
Q1 2021 May 13, 2021	BUY	$5.12 - $8.48 $863,057 - $1.43 Million	168,566 Added 81.19%	376,185 $2.98 Million
Q4 2020 Feb 09, 2021	BUY	$3.16 - $7.03 $115,861 - $257,754	36,665 Added 21.45%	207,619 $1.21 Million
Q3 2020 Nov 12, 2020	SELL	$3.26 - $4.73 $5,163 - $7,492	-1,584 Reduced 0.92%	170,954 $579,000
Q2 2020 Aug 12, 2020	BUY	$1.58 - $4.63 $17,539 - $51,397	11,101 Added 6.88%	172,538 $797,000
Q1 2020 May 06, 2020	BUY	$1.44 - $3.02 $7,623 - $15,987	5,294 Added 3.39%	161,437 $255,000
Q4 2019 Feb 14, 2020	BUY	$2.25 - $3.07 $41,073 - $56,042	18,255 Added 13.24%	156,143 $427,000
Q3 2019 Nov 07, 2019	BUY	$2.67 - $3.65 $63,532 - $86,851	23,795 Added 20.86%	137,888 $405,000
Q2 2019 Aug 12, 2019	BUY	$2.6 - $4.21 $296,641 - $480,331	114,093 New	114,093 $327,000

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account